Nycomed to build API plant in Russia

Swiss drug maker Nycomed is planning an $84-million manufacturing plant in Russia, making it one of the first foreign manufacturers of active pharmaceutical ingredients.

The drugmaker will choose a greenfield site this quarter after two years of study, says Russia Profile.  It will be one of few foreign pharmaceutical companies in Russia, joining French concern Servier, which opened a $56-million plant in Moscow in 2007.

Russia Profile notes that most of Russia's 600 pharma plants are Soviet vintage. "It is a widely held belief that if the government enforces GMP upgrades, then the share of local manufacturers in the pharmaceutical industry will significantly drop--a result diametrically opposed to the government's declared strategy of increasing the share of local manufacturers from some 20 percent in 2008 to 50 percent by 2020," according to the publication.

- here's the Russia Profile article

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.